Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Pheochromocytoma 1Paraganglioma 1Lung Neoplasms 1Hematopoietic and Lymphoid System Neoplasm 1Head and Neck Neoplasms 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 5Nivolumab 4avelumab 3Magnetic Resonance Spectroscopy 3pembrolizumab 2cabozantinib 2atezolizumab 2Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2tremelimumab 1tocilizumab 1relatlimab 1guadecitabine 1eribulin 1erdafitinib 1enfortumab vedotin 1durvalumab 1Watchful Waiting 1Propranolol 1Observation 1Gemcitabine 1Doxorubicin 1Cystoscopy 1Contrast Media 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Ureteral Neoplasms × Contrast Media × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡